Alexion Pharmaceuticals Inc (NASDAQ:ALXN)

123.10
Delayed Data
As of 4:00pm ET
 +0.49 / +0.40%
Today’s Change
72.67
Today|||52-Week Range
128.57
+13.82%
Year-to-Date
Alexion's (ALXN) Ultomiris IV Formulation Gets EC Approval
3:14pm / Zacks.com - Paid Partner Content
Got $1,000? Invest in These 2 Rare Disease Stocks
Nov 17 / MotleyFool.com - Paid Partner Content
Apellis (APLS) Begins Dosing With Pegcetacoplan in ALS Study
Nov 20 / Zacks.com - Paid Partner Content
Should Value Investors Consider Alexion (ALXN) Stock Now?
Nov 16 / Zacks.com - Paid Partner Content
4 of the Cheapest Stocks to Buy Right Now
Nov 18 / MotleyFool.com - Paid Partner Content
Sanofi (SNY) Blood Disorder Candidate Gets FDA's Rejection
Nov 16 / Zacks.com - Paid Partner Content
Apellis' (APLS) Blood Disorder Drug Gets FDA's Priority Tag
Nov 17 / Zacks.com - Paid Partner Content
Got $10,000? 10 Stocks to Buy and Hold for 10 Years
Nov 16 / MotleyFool.com - Paid Partner Content
Got $10,000? Here Are 3 Game-Changing Stocks to Buy
Nov 17 / MotleyFool.com - Paid Partner Content
 

Today’s Trading

Previous close122.61
Today’s open121.64
Day’s range121.23 - 124.38
Volume40,587
Average volume (3 months)1,897,564
Market cap$26.6B
Data as of 4:00pm ET, 11/24/2020

Growth & Valuation

Earnings growth (last year)+2,991.85%
Earnings growth (this year)+14.88%
Earnings growth (next 5 years)+13.00%
Revenue growth (last year)+19.87%
P/E ratio28.8
Price/Sales4.91
Price/Book2.38

Competitors

 Today’s
change
Today’s
% change
SGENSeagen Inc-3.43-2.04%
INCYIncyte Corp-0.71-0.87%
CTLTCatalent Inc-5.15-5.16%
HZNPHorizon Therapeutics...-1.02-1.46%
Data as of 4:00pm ET, 11/24/2020

Financials

Next reporting dateFebruary 4, 2021
EPS forecast (this quarter)$2.52
Annual revenue (last year)$5.0B
Annual profit (last year)$2.4B
Net profit margin48.53%

Profile

Sector
Health Technology
Industry
Biotechnology
No executives to display
Corporate headquarters
Boston, Massachusetts

Forecasts